At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
M6229 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of M6229 Administered as a 120-hour Continuous Infusion at Three Sequential Dose Levels Versus Placebo in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating M6229 and Placebo for Healthy Subjects. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This is a Phase I, single-center, randomized, single-blind, placebo-controlled study in healthy subjects assessing the safety, tolerability and pharmacokinetic profile of three different dose levels of M6229 when administered continuously for 120 hours.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Subjects
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
Enrollment StartNov 2024
Primary CompletionJun 2025
First PostedDec 2025
TodayJul 2026
First PostedDec 16, 2025
Enrollment StartNov 21, 2024
Primary CompletionJun 18, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7 months ago
Interventions
M6229drug
Continuous 120-hour intravenous infusion of M6229
Placebodrug
Continuous 120-hour intravenous infusion of placebo (saline)